S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene

MTAP-deleted Solid Tumors Clinical Trial

Official title: A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP

Status Recruiting

Clinical Trial Summary

This is a first-in-human Phase 1, multicenter, open-label dose escalation study of S095035 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A [MAT2A] inhibitor.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Neoplasms

• NCT number: NCT06188702
• Study type: Interventional
• Source: Servier
• Contact: Institut de Recherches Internationales Servier (I.R.I.S.), Clini
• Phone: +33 1 55 72 60 00
• Email: scientificinformation@servier.com
• Status: Recruiting
• Phase: Phase 1
• Start date: April 29, 2024
• Completion date: May 1, 2026